Gene Therapy: Vector Technology and Clinical Applications

  • Sunyong Tang
  • Kenneth Cornetta
Reference work entry

Abstract

The ability to introduce genetic material into target cells has tremendous potential as a novel means for disease treatment and correction. While gene therapy is still in clinical trials, the past 20 years has seen the development of a large armamentarium of plasmid and viral vectors for human use. Initial trials focused on the correction of genetic diseases, but vectors are now available to deliver pharmacologic agents, reengineer cells, or express ribozyme and inhibitory RNAs that downregulate gene expression. Currently the majority of clinical trials have been in cancer. Approaches directed at malignancies include reengineering of autologous T cells to recognize tumor antigens and eliminate cancer cells, introduction of DNA repair genes into hematopoietic cells to protect them from chemotherapy and foster dose escalation, and introduction of immune stimulatory molecules to foster cancer cell recognition by the immune system. This chapter provides an introduction to gene therapy by illustrating the technology and discussing current clinical applications.

Keywords

Toxicity Leukemia Doxorubicin Methotrexate Measle 

Further Reading

  1. Abonour R, Williams DA, Einhorn E, et al. Efficient retroviral-mediated MDR-1 gene transfer into autologous human long-term repopulating hematopoietic stem cells. Nat Med. 2000;6:652–8.PubMedCrossRefGoogle Scholar
  2. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360:447–58.PubMedCrossRefGoogle Scholar
  3. Bainbridge JWB, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med. 2008;358:2231–9.PubMedCrossRefGoogle Scholar
  4. Cartier N, Hacein-Bey Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science. 2009;326:818–23.PubMedCrossRefGoogle Scholar
  5. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassemia. Nature. 2010;467:318–23.PubMedCrossRefGoogle Scholar
  6. Cornetta K, Smith FO. Regulatory issues for clinical gene therapy trials. Hum Gene Ther. 2002;13:1143–9.PubMedCrossRefGoogle Scholar
  7. Davidson BL, McCray JPB. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011;12:329–40.PubMedCrossRefGoogle Scholar
  8. DiGiusto DL, Krishnan A, Li L, et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med. 2010;2:36–43.CrossRefGoogle Scholar
  9. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346:1185–93.PubMedCrossRefGoogle Scholar
  10. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2004;348:255–6.CrossRefGoogle Scholar
  11. Kay M. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet. 2011;12:316–28.PubMedCrossRefGoogle Scholar
  12. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA. 2006;103:17372–7.PubMedCrossRefGoogle Scholar
  13. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med. 2008;358:2240–8.PubMedCrossRefGoogle Scholar
  14. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011;12:341–55.PubMedCrossRefGoogle Scholar
  15. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet. 2011;12:301–15.PubMedCrossRefGoogle Scholar
  16. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther. 2005;16:1016–27.PubMedCrossRefGoogle Scholar
  17. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–33.PubMedCrossRefGoogle Scholar
  18. Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990;323:570–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Sunyong Tang
    • 1
  • Kenneth Cornetta
    • 2
  1. 1.Indiana University Vector Production Facility, Department of Medical and Molecular GeneticsIndiana University School of MedicineIndianapolisUSA
  2. 2.Department of Medical and Molecular GeneticsIndiana University School of MedicineIndianapolisUSA

Personalised recommendations